Company intelligence / Profile preview

Papillex

United States

Ownership: Private
Development stage: Other

Overview

A randomized, placebo-controlled clinical trial (NCT06979180) is underway to investigate Papillex® for regression of abnormal cervical cells caused by HPV. Preliminary studies of Papillex ingredients (such as EGCG and AHCC) suggest immune and virological benefits, but company-level clinical outcome results are not yet published.[5][3][4]

Therapeutic areas: Infectious DiseasesWomen's Health
Modalities: Non-pharmacological therapySmall molecule (vitamin/mineral/antioxidant blend)Botanical extract
Industry: Food & Nutrition

Beyond the preview

Go deeper on Papillex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Papillex.

Explore the full profile